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Infection of mice with sporozoites of Plasmodium berghei or Plasmo-
dium yoelii has been used extensively to evaluate liver-stage protec-
tion by candidate preerythrocytic malaria vaccines. Unfortunately,
repeated success of such vaccines in mice has not translated readily to
effective malaria vaccines in humans. Thus, mice may be used better
as models to dissect basic parameters required for immunity to
Plasmodium-infection than as preclinical vaccine models. In turn, this
basic information may aid in the rational design of malaria vaccines.
Here, we describe a model of circumsporozoite-specific memory CD8
T cell generation that protects mice against multiple P. berghei
sporozoite challenges for at least 19 months. Using this model we
defined a threshold frequency of memory CD8 T cells in the blood that
predicts long-term sterilizing immunity against liver-stage infection.
Importantly, the number of Plasmodium-specific memory CD8 T cells
required for immunity greatly exceeds the number required for
resistance to other pathogens. In addition, this model allowed us to
identify readily individual immunized mice that exceed or fall below
the protective threshold before infection, information that should
greatly facilitate studies to dissect basic mechanisms of protective
CD8 T cell memory against liver-stage Plasmodium infection. Further-
more, the extremely large threshold in memory CD8 T cell frequencies
required for long-term protection in mice may have important impli-
cations for development of effective malaria vaccines.
Infection of humans with Plasmodium species, the causativeagents of malaria, results in severe morbidity and mortality in
the developing world (1), effects that have stimulated intense
efforts to develop efficacious vaccines. Protective CD8 T cell
immunity against liver-stage Plasmodium infection has been
demonstrated after vaccination of rodents with irradiated or
genetically attenuated parasites and after subunit vaccination
against liver-stage antigens (2–12). Immunity in rodents can last
for 6–12 months (3, 4, 7, 13), but in several studies also seems to
wane with time (7, 14–16). Although irradiated sporozoite
vaccines also protect humans (17–19), current subunit vaccina-
tions limit liver-stage infection but rarely prevent blood-stage
parasitemia (20). Importantly, it remains unknown whether
sterilizing long-term immunity to Plasmodium infection can be
achieved through subunit vaccines that predominantly evoke
memory CD8 T cell responses and, if so, precisely what memory
T cell parameters will be required.
A single mosquito bite delivers a few hundred infectious Plas-
modium sporozoites into dermal tissues (21), a fraction of which
traffic to the liver and establish hepatocyte infection leading to
release of blood stage parasites 2 days (P. berghei infection of mice)
(22) or 6–8 days (P. falciparum infection of humans) (23) later. As
such, infected cells may represent as few as 1 in 109 hepatocytes in
humans and 1 in 106 hepatocytes in mice. Thus, both temporal and
spatial challenges (analogous to rapidly finding a few needles in a
haystack) must be overcome forPlasmodium-specific memory CD8
T cells to deal with all infected hepatocytes and prevent the
symptomatic blood stage of infection. The use of mouse models of
Plasmodium infection to determine how the immune system can be
manipulated by immunization to overcome these challenges may
have important implications for rational design of malaria vaccines.
Filling this knowledge gap will require immunization models to
reliably generate memory CD8 T cells that confer long-term
immunity, so that the characteristics of these populations leading to
protection can be defined. Here, we describe an immunization
strategy that generates P. berghei circumsporozoite (CS)-specific
memory CD8 T cells capable of protecting mice from multiple
sporozoite challenges for at least 19 months. Studies with this model
revealed that the threshold in memory CD8 T cell numbers
required for long-term protection from sporozoite infection reflects
a substantial fraction of the CD8 T cell compartment, a finding with
potentially important implications for development of effective
vaccines to protect against human malaria.
Results
Generation of CS-Specific Memory CD8 T Cells. Protective immunity
to infection may be influenced by both the functional attributes
and numbers of memory CD8 T cells (24–26). We reasoned that
the extremely low frequencies of infected hepatocytes might
dictate that a large number of memory CD8 T cells would be
required to ensure all infected liver cells are located and dealt
with to prevent blood stage infection. To test this hypothesis, we
made use of an accelerated ‘‘prime-boost’’ immunization strat-
egy, developed in our laboratory, that rapidly generates large
numbers of memory CD8 T cells (27). BALB/c mice initially
were immunized with mature dendritic cells (DC) coated with a
P. berghei epitope (CS252–260, also known as ‘‘Pb9,’’ DC-CS
immunization) that is a target of protective CD8 T cells (8). As
we reported for other epitopes (27), DC-CS immunization
resulted in accelerated acquisition of memory characteristics
(CD127hi, KLRG-1lo, IL-2) by the responding CD8 T cells (Fig.
1A), including the ability to respond to booster immunization
with recombinant attenuated (actA-, inlB-deficient) (28) L.
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monocytogenes expressing the CS252–260 epitope (here on re-
ferred to as ‘‘LM-CS252’’) that is embedded within a secreted
ovalbumin fusion protein and does not contain known antibody
or CD4 T cell epitopes. This DC-CS  LM-CS immunization
generated large frequencies (Fig. 1B) and total numbers (Fig.
1C) of effector and memory CS252-specific CD8 T cells that were
10-fold greater than generated by DC-CS or LM-CS252 immu-
nization alone. Splenic memory CD8 T cell frequencies and total
numbers (Fig. 1B and C) in all groups were maintained stably
between day 41 and day 96 and, of critical importance for
resistance to liver-stage Plasmodium infection, numbers of
CS252-specific CD8 T cells in the liver and spleen were propor-
tional at day 54 (Fig. 1D and E) and at day 72 (data not shown).
Additionally, the frequency of CS252-specific CD8 T cells of all
peripheral blood lymphocytes (PBLs) was proportional to the
numbers of antigen-specific cells in the spleen and liver (Fig. 1F).
Thus, DC-CS  LM-CS immunization rapidly generated large
and stable populations of P. berghei-specific memory CD8 T cells
in the spleen, PBL, and liver.
It should be noted that this immunizations strategy, based on
a short peptide epitope prime and epitope-fusion protein boost,
does not induce a detectable CD8 negative (i.e., CD4 T cell)
IFN- response (data not shown). Also, antibodies induced by
this vaccination would be directed either to the CS252-MHC class
I complex (after DC-CS252 immunization) or to the short CS
epitope embedded in the ovalbumin carrier protein (LM-CS252
boost). If such antibodies are induced, they are unlikely to react
in a meaningful way with the conformationally intact CS protein
expressed by P. berghei sporozoites. Thus, our immunization
strategy permits a focus on the ability of CS252-specific CD8 T
cells to provide immunity against sporozoite challenge.
DC-CS  LM-CS CD8 T Cells Prevent Blood-Stage Parasitemia. To
evaluate individual-to-individual variability and to mimic sam-
pling of humans, frequencies of memory CS252-specific CD8 T
cells of all PBL were determined at day 98 in individual mice.
DC-CS- and LM-CS252-immunized mice had 0.2% CS252-
specific PBL, whereas DC-CS  LM-CS mice exhibited 2%
CS252-specific PBL (Fig. 2A). This frequency represented a
substantial fraction (21%) of circulating CD8 T cells in the
DC-CS  LM-CS mice (data not shown). All naı¨ve and LM-
CS252-immune and 11 of 12 DC-CS-immune mice developed
blood stage parasitemia after sporozoite challenge (Fig. 2B). In
contrast, 10/11 DC-CS  LM-CS mice were protected, with
blood-stage parasitemia observed only in the mouse that had the
lowest frequency of CS252-specific PBL (0.5%). These data
suggest that immunity to liver-stage parasites may depend on the
numbers of antigen-specific memory CD8 T cells.
CS-Specific Memory CD8 T Cells Afford Long-Term Sterile Immunity.
Although many vaccination strategies are successful in protect-
ing rodents from sporozoite challenge for several months (29),
the feasibility of long-term immunity based solely on memory
CD8 T cells remains unknown. A representative analysis of
DC-CS LM-CS mice revealed106 CS252-specific CD8 T cells
per spleen on day 209 (Fig. 3A), a number similar to that
observed at day 41 (Fig. 1). One hundred percent of additional
mice from this group were protected from sporozoite challenge
on day 210, indicating that CD8 T cells in DC-CS LM-CS mice
can protect for at least 7 months (Fig. 3B). Immunity in
malaria-endemic areas must protect the host from repeated
sporozoite exposures. To address this issue and to evaluate
further the duration of memory and protection, CS252-specific
Fig. 1. Generation and maintenance of P. berghei CS252-specific CD8 T cells. BALB/c mice were primed with 3 105 bone marrow-derived dendritic cells coated
with CS252–260 (DC-CS). Seven days later DC-CS mice were boosted with 2 107 LM-CS252 (DC-CS LM-CS) or naive mice were primed with 7 106 LM-CS252 (LM-CS).
(A) Frequency and phenotype of splenic CD8 T cells that are CS252 specific as determined by ICS 8 days after DC-CS prime. (B) Frequency of splenic CD8 T cells that
are CS252 specific on days 14, 41, and 96 as determined by ICS. Profiles from representative mice are shown; numbers represent mean SD; n 3 per group. (C)
Total number (mean  SD, n  3 per group) of CS252-specific CD8 T cells in the spleen on various days after initiation of immunization. Total number (mean 
SD, n  3 per group) of CS252-specific CD8 T cells (D) in the spleen and (E) liver or (F) percent CS252-specific CD8 T cells of all PBL 54 days after initiation of
immunization for the indicated groups. Data are representative of three experiments.
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PBL were determined at day 406 in the 5 mice that had resisted
challenge at day 210 and in an additional group of unchallenged
DC-CS  LM-CS mice (Fig. 3C). Both groups exhibited 2%
CS252-specific PBL and were protected from sporozoite chal-
lenge at day 422 (Fig. 3C). Both groups of mice maintained high
levels of CS252-specific CD8 T cells (2% of all PBL on average),
and all resisted additional sporozoite challenges at day 455, day
485, and day 565 (19 months after immunization, data not
shown). Interestingly, we did not observe ‘‘boosting’’ in memory
cell frequencies in these groups despite the repeated challenges
(data not shown). This may result from the very large memory
populations already present in the DC-CS  LM-CS immune
mice or suggest that the amount of antigen present in the
challenges was insufficient to cause noticeable boosting in
memory numbers. However, it is possible that the repeated
challenge infections induced antibody and CD4 T cell responses
that contributed to resistance of multiply challenged mice. These
issues are under investigation. Over multiple experiments, 136/
141(96%) of DC-CS  LM-CS mice were protected from
initial sporozoite challenge from day 28 to day 422 after immu-
nization. Thus, CD8 T cell protection can last for 14 months,
and immunity is maintained up to 19 months in the face of
multiple sporozoite challenges. Importantly, the ability to gen-
erate large numbers of CS252-specific memory CD8 T cells and
sterilizing immunity to sporozoite challenge was not limited to
DC-CS  LM-CS immunization but also could be achieved by
boosting LM-CS252-immune mice at40 days with a higher dose
of LM-CS252 (LM-CS  LM-CS data in Fig. 4). These data
demonstrate that single-epitope specific-memory CD8 T cells
can provide long-term sterilizing immunity against Plasmodium
sporozoite challenge.
Defining the Threshold Frequency of Memory CD8 T Cells Required for
Sterilizing Immunity. The reliable long-term protection afforded
by DC-CS LM-CS immunization suggests that this model may
be well suited to dissect the basic parameters of CD8 T cell
immunity to liver-stage Plasmodium infection. Initially, we
sought to determine whether a threshold frequency of protective
memory CD8 T cells could be defined with this immunization
model. BALB/c mice were primed with DC-CS and then boosted
with a range of LM-CS252 (from 2  104-2  107) to stimulate
different magnitudes of CD8 T cell memory. Because DC-CS,
LM-CS252, and DC-CS  LM-CS immunization stimulated
memory CD8 T cells that exhibited some differences in pheno-
type (for example, CD27 and CD62L expression and IL-2
production) [supporting information (SI) Fig. S1], we investi-
gated whether boosting the mice with different doses of LM-
CS252 altered the phenotype of the CS252-specific CD8 T cells.
Importantly, the surface expression of certain memory markers
(CD27, CD62L, and CD127) was similar in all groups, as was the
LM-CSDC-CS DC+LM
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Fig. 2. CS252-specific memory CD8 T cells afford protection for 3 months
against a P. berghei sporozoite challenge. (A) Frequency of CS252-specific CD8
T cells in the PBL 98 days after priming. Data (mean  SD) are from 10 to 12
mice per group. (B) Percentage total PBL that are CS252-specific CD8 T cells as
determined by ICS in individual mice from the indicated immunization group
before challenge. Filled circles indicate naı¨ve or immune mice that developed
blood-stage malaria after a challenge with 1000 P. berghei sporozoites.
Numbers represent protected mice/total challenged for each group. n.d., not
determined.
A
C DC+LM
2nd
challengeDC+LM
Protected5/56/6
Naive
0/9
n.d.
B
Naive
DC-CS + LM-CS
Challenged Protected % Protected
5
5
0
5
0%
100%
Day 210
Fig. 3. Long-term protection against multiple P. berghei sporozoite chal-
lenges. BALB/c mice were primed with 5 105 splenic DC (sDC)-CS and boosted
with 2  107 LM-CS252. (A) Total number (mean  SD, n  3 mice per day) of
CS252-specific CD8 T cells in the spleen on various days after the start of
immunization. (B) Naı¨ve or DC-CS LM-CS mice were challenged with 1000 P.
berghei sporozoites on day 210. (C) The percent of total PBL that are CS252-
specific CD8 T cells at day 406 after immunization was determined by ICS from
individual unchallenged or previously challenged DC-CS LM-CS immunized
mice. Naı¨ve and immune mice were challenged with 1000 P. berghei sporo-
zoites at day 422. Filled circles indicate mice that developed blood-stage
malaria. Numbers represent protected mice per total challenged for each
group. n.d., not determined.
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fraction of CS252-specific memory cells that could produce IL-2
after in vitro stimulation (Fig. 5A and Fig. S2). Thus, differences
in the resistance of individual immunized mice probably would
be based on the number of memory CD8 T cells. The average
frequency of memory CD8 T cells in the PBL of each group
increased with increasing doses of LM-CS252 boosting, as did the
frequency of protected mice in each group (Fig. 5B). Because
there was individual-to-individual variation within each group,
and the phenotypes of the memory CD8 T cells were similar,
we evaluated all immunized mice based on the frequency of
CS252-specific CD8 T cells and protection. Strikingly, 20 of 22
DC-CS  LM-CS mice that had  1% CS252-specific PBL were
protected from sporozoite challenge at day 98 after immuniza-
tion, whereas only 1 of 16 similarly immunized mice with 1%
CS252-specific PBL were protected (Fig. 5B). When we include
all DC-CS  LM-CS mice in which memory CD8 T cells have
been evaluated in the blood at day 98 or later, our data
demonstrate a 97% chance of protection from sporozoite chal-
lenge in mice containing  1% CS252-specific PBL and a 6%
chance of protection in mice with 1% CS252-specific PBL (Fig.
5C). Thus, long-term sterilizing immunity to P. berghei infection
in this model requires maintenance of CS252-specific memory
CD8 T cells that exceed a large ( 1%) but definable frequency
of PBL (Fig. 5C).
Immunity to P. berghei Requires More CD8 T Cells than Other Patho-
gens. Although it is clear that the magnitude of CD8 T cell
memory can influence resistance to infection (25, 26), there are
few data comparing the actual numbers of antigen-specific T
cells required for protection against diverse pathogens. To
address this issue, we determined that adoptive transfer of 10,000
memory CD8 T cells reduced infection by the liver pathogen
Listeria monocytogenes by 100-fold (Fig. S3). Similarly, adop-
tive transfer of 85,000 memory CD8 T cells dramatically
decreased virus titers after lymphocytic choriomeningitis virus
A
Naive LM-CS
LM-CS(d44)
+LM-CS
Protected1/8 0/5 10/10
n.d.
B
Fig. 4. LM-CS252-primed and LM-CS252-boosted BALB/c mice are protected
against a P. berghei sporozoite challenge. (A) In an initial experiment to
evaluate conventional prime-boost responses, BALB/c mice were primed with
7  106 LM-CS252 and boosted with 2  107 LM-CS252 53 days later (LM-
CS(d53)LM-CS). On the day of the LM-CS boost, naive BALB/c mice were
primed with 7 106 LM-CS252 (LM-CS). (A) Total number (mean SD,n 3 per
group) of CS252-specific CD8 T cells in the spleen and liver and percentage of
PBL at day 61 after boost or first immunization was determined by ICS. (B) In
a second experiment BALB/c mice were primed with 7  106 LM-CS252 and
boosted with 2 107 LM-CS252 44 days later (LM-CS(d44) LM-CS). On the day
of the LM-CS252 boost, naive BALB/c mice were primed with 7  106 LM-CS252
(LM-CS). Percentage of total PBL that were CS252-specific CD8 T cells at day 75
after the last immunization was determined by ICS in individual mice. Filled
circles indicate naı¨ve or immune mice that developed blood-stage malaria
after a challenge with 800 P. berghei sporozoites on day 83 after boost.
Numbers represent protected mice per total challenged for each group. n.d.,
not determined
B
Naive
2x104
LM-CS
2x105
LM-CS
2x107
LM-CS
2x106
LM-CS
Protected1/22 1/10 5/10 8/10 7/7
n.d.
1%
A
≥1%
<1%
Challenged Protected % Protected
58
16
56
1
97%
6%
%CS252-
specific PBL
Day 98-422
C
Fig. 5. Numerical requirements for sterile immunity mediated by CS252-
specific CD8 T cells. BALB/c mice were primed with 2.5 105 splenic DC-CS and
boosted with titrating doses of LM-CS252 (2 104, 2 105, 2 106, or 2 107).
(A) Phenotype of PBL CS252-specific CD8 T cells as determined by ICS at day 98.
Data (mean SD) are from 10 mice per group except for 2 107, in which n
7. (B) Before sporozoite challenge the percentage of total PBL CS252-specific
CD8 T cells was determined in individual mice by ICS. Naı¨ve and immune mice
were challenged with 1000 P. berghei sporozoites. Filled circles indicate mice
that developed blood-stage malaria. n.d.  not determined. (C) Cumulative
results from DC-CS  LM-CS immunized mice in which the frequency of PBL
CS252-specific CD8 T cells was determined before challenge with sporozoites.
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infection (30). Finally, the presence of 50,000 memory CD8 T
cells in the spleen converted a lethal L. monocytogenes infection
into a sublethal infection that was cleared from all mice (26).
This last situation is analogous to the biological ‘‘bar’’ that must
be overcome for CD8 T cell protection against Plasmodium
infection, in which elimination of all infected hepatocytes is
required for survival of the mouse. Thus, the 1% of CS252-
specific PBL threshold (equivalent to 106 in spleen and 2 
105 in liver) required for long-term sterilizing immunity to
liver-stage Plasmodium infection is 100-1000-fold higher than
the numbers of memory CD8 T cells required for meaningful
immunity against a bacterial or viral pathogen.
Discussion
In this study, we developed a model of epitope-specific immu-
nization to generate large memory CD8 T cell responses capable
of protecting mice from sporozoite challenges. Although several
studies have shown that protection from challenge at short
intervals after boosting correlates with large CD8 T cell re-
sponses (6, 8, 9, 31, 32), our results extend the field in at least 3
ways. First, we demonstrate that memory CD8 T cells specific for
Plasmodium liver-stage antigens are capable of providing long-
term sterilizing immunity, approaching the entire lifespan of the
laboratory mouse. Protection lasting 6 months has been de-
scribed only for immunization with irradiated or genetically
attenuated sporozoite immunizations, suggesting that long-term
immunity after subunit vaccination may not be possible. Our
results clearly argue against this notion. Second, our results also
reveal that a large but definable threshold of memory CD8 T
cells is required for protection against sporozoite challenge.
Importantly, this threshold greatly exceeds the number of mem-
ory CD8 T cells required for protection against specific bacterial
and viral pathogens. These results suggest that the biology of the
pathogen will affect the number of memory CD8 T cells required
for resistance to infection. In the case of Plasmodium infection,
the low frequency of infected hepatocytes in combination with
the requirement of preventing even 1 infected cell from releasing
blood-stage parasites provides a challenge to the immune system
that requires commitment of a substantial fraction of the CD8 T
cell repertoire to achieve sterilizing immunity. Third, these data
describe a novel model system that should facilitate studies to
address how CD8 T cells provide immunity against liver-stage
Plasmodium infection.
Our results were generated with an epitope-specific immuni-
zation protocol in inbred mice, and this scenario is unlikely to
have immediate relevance as a vaccine strategy in humans.
Although the mouse in general and our approach specifically
may have limitations as a preclinical model, the results still may
have relevance for understanding why subunit vaccines that
evoke sterilizing immunity against human malaria have been
difficult to obtain. For example, accumulating data from human
clinical trials show that current prime-boost immunizations
generate Plasmodium-specific T cell responses in the range of
0.1% of PBL at the peak after boosting and 0.01% at memory
stages (20, 33–36). These frequencies are 10-fold and 100-fold
lower than required to protect mice from Plasmodium infection
and consist mainly of CD4 T cells, which may explain why these
vaccines delay the onset but rarely prevent blood-stage para-
sitemia (20, 36). Clearly, delayed onset of blood-stage para-
sitemia indicates partial protection by these vaccines, and such
partial protection could have real benefits in malaria-endemic
areas. However, results from our model suggest that additional
or stronger booster immunizations may be required to generate
memory CD8 T cell frequencies that exceed the threshold for
optimal resistance to Plasmodium infection in humans. Further-
more, it remains to be determined whether immunization against
multiple liver-stage antigens will decrease the large frequency of
CS-specific memory CD8 T cells required for sterilizing immu-
nity. The model system we describe here is ideally suited to
address this question.
Alternatively, vaccination of humans to achieve the large
frequencies of memory CD8 T cells that are required for
sterilizing immunity to Plasmodium infection in mice may not be
feasible. In this regard, CD8 T cells are not the only effectors of
immunity to Plasmodium infection, and efforts are underway to
develop vaccines that also engage Plasmodium-specific CD4 T
cells and antibodies and that are capable of targeting multiple
stages of the parasite infection (23). Importantly, the relation-
ships between these various arms of the immune response
resulting in the most effective resistance to Plasmodium infection
are unknown. The model system described here is well suited for
determining these relationships, because it permits quantitative
assessment of whether and how Plasmodium-specific antibodies
and CD4 T cells decrease the threshold frequencies of CS-
specific CD8 T cells required for protective immunity.
In addition, the precise mechanisms and pathways required for
CD8 T cell immunity to liver-stage Plasmodium infection remain
to be defined. The DC-CS  LM-CS immunization approach
used here provides an informative and reliable model in which
immune and susceptible mice can be identified before infection.
The ability to differentiate prospectively between resistant and
susceptible subjects provides a level of resolution that is partic-
ularly important for liver-stage studies because the host must be
killed for tissue sampling before the outcome of challenge is
known. This feature of the model will facilitate studies to address
in detail the molecular and cellular features of long-term CD8
T cell protection against liver-stage Plasmodium infection. In
turn, this basic information should be useful in devising the most
efficacious malaria vaccines.
Methods
Mice and Immunizations. BALB/c mice were housed at the University of Iowa
and Iowa State University animal care units. Mice were primed with DC (2.5
105-5  105) coated with CS252–260 or with LM-CS252 (7  106) through i.v.
injections. DC-primed mice were boosted 7 days later with 2 107 LM-CS252 or
with titrating doses of LM-CS252 (2 104, 2 105, 2 106, or 2 107). (Detailed
methods are available in SI Text.)
Quantification of Antigen-Specific T Cells. The total number of spleen CS252-
specific CD8 T cells was determined by ICS for IFN- after 5 h of incubation in
brefeldin A in the presence or absence of CS252–260. Total liver CS252-specific
CD8 T cells and the percent of PBL that were CS252-specific were determined by
ICS for IFN- after 5 h of incubation in brefeldin A in the presence or absence
of CS252–260-coated P815 cells.
Mosquito Infections.Anopheles stephensi (Liston) strain STE2 (MR4–128, MR4,
ATCC) were reared in controlled environments (27°C  1°C and 80%  5%
relative humidity) and a 16:8-hour photoperiod. Mosquitoes were fed on
anesthetized mice 3 days after subpassage or when parasitemia reached
5–20%. To confirm infection before sporozoite collection, oocyst prevalence
and intensity were monitored 7–14 days after exposure.
Sporozoite Challenge. P. berghei (ANKA strain clone 234) sporozoites were
isolated from the salivary glands of infected A. stephensi. Naı¨ve and immu-
nized mice were challenged with 1000 sporozoites i.v. unless otherwise noted.
Identification of Protected Mice. Thin blood smears were performed 7 to 12
days after sporozoite challenge. Parasitized red blood cells were identified by
Giemsa stain. Protected mice were defined as those not having blood-stage
parasites.
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Mice. BALB/c mice for DC immunizations were obtained from
the National Cancer Institute and housed at the University of
Iowa. All experiments were approved by the University of Iowa
Institutional Animal Care andUse Committee. BALB/c mice for
mosquito infections were obtained fromHarlan Sprague Dawley
and maintained in a laboratory animal suite at Iowa State
University. All mice were treated and handled in accordance
with guidelines established by the Institutional Animal Care and
Use Committee at Iowa State University.
Dendritic Cells.Mice were primed with between 2.5 105 and 5
105 BMDC or splenic DC (sDC) coated with CS252–260. Priming
of mice with peptide-coated bone marrow dendritic cells
(BMDC) followed by early boosting with Listeria monocytogenes
has been described previously (1). Briefly, bone marrow cells
were depleted of CD8, CD4, and B220 cells by antibody-
mediated complement lysis. Bone marrow cells were cultured in
recombinant GM-CSF (1000 U/ml) and recombinant IL-4 (27
U/ml) for 6 days with the addition of LPS (100 ng/ml) for the last
14–18 h as a maturation stimulus. BMDCwere pulsed with 2 M
CS252–260, and epitope-coated BMDC were isolated using anti-
CD11c microbeads (Miltyni Biotec) resuspended in saline and
injected i.v.
sDC were isolated after i.p. injection of BALB/c mice with 5 
106 B16 cells expressing Flt3L (provided by M. Prlic andM. Bevan,
University of Washington). Two weeks later, mice were injected
with 2 g LPS i.v. to mature the DC. Spleens were harvested 16 h
later and were digested with DNase and collagenase for 20 min at
37°C/7% CO2 with shaking (120 RPM). Spleen pieces were forced
through a nylon cell strainer (70 m) to generate a single-cell
suspension, RBC were lysed, and splenocytes were resuspended in
2 parts supplemented RPMI-1640 to 1 part B16-Flt3L-conditioned
media recombinant GM-CSF (1000 units/ml)  2 M CS252–260
and incubated 2 h at 37°C/7%CO2 with shaking (100 RPM). Spleen
cells were washed, and CD11c cells were isolated using anti-
CD11c microbeads (Miltyni Biotec). sDC were resuspended in
saline and injected i.v. BMDC and sDC were analyzed by cell-
surface staining for CD11c ( 85%) before injection. CD11c cells
also were analyzed for expression of CD86 ( 85%) and MHC II
( 90%).
Bacteria. Listeria monocytogenes expressing P. berghei CS252–260
(LM-CS) was generated by ANZA Therapeutics. The LM-CS
strain is an attenuated strain because of the in-frame deletion of
both the actA and inlB genes (2). The CS252–260 epitope is f lanked
by 3 native amino acids on either side and is secreted as a fusion
peptide (2). Frozen aliquots of LM-CS were diluted in tryptic soy
broth containing 50 g/ml streptomycin (TSB-strep) and grown
to an OD600 of0.1, which equates to 108 LM/ml. LM-CS cells
were diluted in saline so that the target dose would be delivered
in 0.2 ml. Mice were primed and boosted through the tail vein
with 7 106 LM-CS or with 2 107 LM-CS. In some cases mice
were boosted with titrating doses of LM-CS (2  104, 2  105,
2 106, or 2 107). The number of injected bacteria was verified
by plating diluted aliquots onto tryptic soy agar containing 50
g/ml streptomycin (TSA-Strep).
Quantification of Antigen-Specific T Cells. Single-cell suspensions
from spleens were treated with Tris-ammonium chloride to lyse
RBC and were washed with supplemented RPMI-1640 before
stimulation. Livers were perfused with 10 ml cold HBSS through
the hepatic portal vein. After removal of the gall bladder, the
liver was excised and was forced through a wire mesh to make a
single-cell suspension. Cells were filtered through a 70-M filter
and were rinsed with HBSS. Liver cells were spun at 400 g for 5
min at 4°C. Cells were resuspended in 15 ml of 35% Percoll/
HBSS at room temperature and were spun at 500 g with no
brakes for 10 min at room temperature. Pelleted cells were
treated with Tris-ammonium chloride to lyse RBC, were washed
with HBSS, and were centrifuged at 400 g for 5 min at 4°C. PBL
were obtained by treating blood with Tris-ammonium chloride to
lyse RBC followed by 2 washes.
Total spleen CS252-specific CD8 T cells were determined by
ICS for IFN- after 5 h of incubation in brefeldin A (Biolegend)
in the presence or absence of 200 nM CS252–260 as previously
described (1). Total liver CS252-specific CD8 T cells and the
percent of PBL that were CS252-specific CD8 T cells were
determined by ICS for IFN- after 5 h of incubation in brefeldin
A in the presence or absence of CS252–260-coated P815 cells.
Antibodies. The following antibodies from Biolegend were used:
IgG2A-PE (RTK2758), CD127-PE (SB/199), and IL-2-PE
(JES6–5H4). The following antibodies from eBioscience were
used: CD8-FITC (53–6.7), CD27-PE (LG.7F9), KLRG1-APC
(2F1), and Golden Syrian Hamster IgG-APC. The following
antibodies from BD PharMingen were used: IFN--APC and
CD62L-PE (MEL-14).
Passage of Blood-Stage P. berghei ThroughMice.Modified P. berghei
challenge protocols were followed (3, 4). Briefly, mice were
infected with a P. berghei (ANKA strain clone 234) cryopre-
served stock stabilate via i.p. injection. To visualize P. berghei
infected erythrocytes, thin blood smears were prepared using the
Hema 3 stain set (Fisher Diagnostics ). Mice were anesthetized
with a ketamine/xylazine mix at 80:8 mg/kg for blood collection
and mosquito feeding. Parasitemic blood was collected via
cardiac puncture into a heparinized needle and syringe, and 0.1
ml was subpassaged immediately to a new mouse. Mosquitoes
were fed on anesthetized mice 3 days after subpassage or when
parasitemia reached 5% to 20%.
Mosquitoes.Anopheles stephensi (Liston) strain STE2 (MR4–128,
MR4, ATCC ) were reared in controlled conditions (27°C 1°C
and 80% 5% relative humidity) with a 16:8-hour photoperiod.
Adult mosquitoes were housed in 0.5-L paper cartons and
provided 10% sucrose (wt/vol) ad libitum. Sucrose was replaced
with a water-soaked cotton ball 24 h before mosquito feeding.
After exposure, engorged females were transferred immediately
to holding cages and maintained at 20°C  1°C and 80%  5%
relative humidity with a 16:8-hour photoperiod. To confirm
infection before sporozoite collection, oocyst prevalence and
intensity were monitored 7–14 days after exposure. A. stephensi
midguts were dissected and stained using 0.5% aqueous Eosin Y
(JT Baker) then viewed with bright field at 100 magnification.
Sporozoite Challenge. Salivary glands from P. berghei-infected A.
stephensi were dissected using a stereomicroscope. Salivary glands
were disrupted using a 0.1-ml dounce (Fisher Scientific) to release
sporozoites. Sporozoites were quantified and injected i.v. into mice.
Identification of Infected and Protected Mice. Thin blood smears
were performed 7 and 12 days after sporozoite challenge. Parasit-
ized RBC were identified by Giemsa stain. Protected mice were
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Fig. S1. Phenotype of memory CS252-specific CD8 T cells. BALB/c mice were primed with 5 105 DC coated with CS252–260 (DC-CS) or with 7 106 LM-CS252.
Seven days later DC-CS mice were boosted with 2.8  107 LM-CS252 (DC-CSLM--CS). Phenotype of (A) spleen, (B) liver, and (C) blood CD8 T cells that are CS252
specific on day 61 as determined by ICS. One of 3 representative histograms is shown. Data are representative of 2 experiments.
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Fig. S2. Similar phenotype of CS252-specific CD8 T cells in mice given increasing doses of LM-CS252 boost. Mice were primed with 2.5 105 DC-CS and boosted
with increasing doses of LM-CS252. Peripheral blood CS252-specific CD8 T cells were identified by ICS and analyzed for the expression of CD27, CD62L, and CD127
and for the production of IL-2 on day 86. Shaded histograms are the isotype control, and open histograms are the indicated marker. Three representative
examples from each group (2  104, 2  105, and 2  106, n  10) and (2  107, n  7) are shown.
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Fig. S3. Anti-listerial immunity provided by low number of memory CD8 T cells. (A) Experimental design. Purified naive OT-I Thy1.1 CD8 T cells (500/mouse)
were transferred into naive B6 Thy1.2 mice, and 1 day later mice were immunized with Att LM-Ova (5 106 cfu/mouse). At day 40 after immunization, OT-I were
purified from the spleens of immune mice by positive selection (Thy1.1) and were transferred (1  104/mouse) into naive B6 recipients 1 day before high-dose
virulent LM-Ova infection (1 106 cfu/mouse). The group of naive mice (naı¨ve) that did not receive memory OT-I cells served as controls. (B) Frequency of OT-I
CD8 T cells in the blood at the indicated days after primary LM infection. (C) On day 2 after high-dose virulent LM-Ova infection, bacterial numbers were
determined in the liver. Data are presented as mean  SD of 3 mice per group. One of 2 similar experiments is shown.
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